Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

140.15 +0.44 (+0.31%)
Streaming Delayed Price Updated: 2:54 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
72 73 Next >
News headline image
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
News headline image
Gilead Sciences's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Gilead Sciences ↗
 
Via Benzinga
News headline image
Breaking Down Gilead Sciences: 10 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With GILD ↗
 
Via Benzinga
News headline image
Gilead Sciences's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On ↗
Nasdaq 100 index falls to its lowest level since June amid volatility. Despite a brief boost from Q2 GDP growth and decreasing prices, it dropped 4.7% in 2 sessions. 
Via Benzinga
News headline image
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Stocks That Can Help You to Get Richer in 2024 and Beyond ↗
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well. 
Via The Motley Fool
News headline image
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price ↗
Gilead Sciences' lenacapavir, marketed as Sunlenca, is under scrutiny for its $42,250 annual price despite research suggesting it could be produced for $40. Campaigners are urging for global price... 
Via Benzinga
News headline image
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial ↗
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
News headline image
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst ↗
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
Via Benzinga
News headline image
Biotech Bull Market Is Intact But SMIDs Are Too Volatile ↗
It was another wild week for the market as it had to contend with a lot of news. 
Via Talk Markets
News headline image
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
News headline image
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now. ↗
This fund has a basket of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
News headline image
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names ↗
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
Via InvestorPlace
News headline image
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays ↗
These three dividend vehicles could provide reliable passive income. 
Via The Motley Fool
News headline image
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 ↗
Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market. 
Via InvestorPlace
News headline image
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
News headline image
3 Dividend Growth Stocks to Buy and Hold ↗
What's better than a dividend? A dividend that's growing. 
Via The Motley Fool
News headline image
Is Iovance Biotherapeutics a Millionaire Maker? ↗
This biotech's future is bright, but how good could it get for investors? 
Via The Motley Fool
News headline image
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024 ↗
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
News headline image
3 Underappreciated Stocks About to Break Their Chains ↗
Explore these underappreciated stocks ready for growth and get an in-depth analysis, forecasts, and news on these potential breakout stocks. 
Via InvestorPlace
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.